We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cold, Appetite and Weight Loss in Individuals With Obesity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05076357
Recruitment Status : Recruiting
First Posted : October 13, 2021
Last Update Posted : April 27, 2022
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Eric Doucet, University of Ottawa

Brief Summary:

This study is an 8 week weight loss intervention with 3 randomly assigned groups: DIET, cold exposure (CE), and DIET+CE. The study will be a total of 13 weeks. All participants will undergo a screening session, two experimental sessions at baseline and two experimental sessions after the intervention.

There will be a control (ambient) experimental session and a cold exposure experimental session These will be done in a randomized order both before and after the intervention. Therefore, a total of 5 lab visits will be required for all participants regardless of group outside of their assigned group intervention. Participants in the CE and DIET+CE groups will report to the laboratory every 2nd day for the 8 week intervention to undergo cold exposure as outlined below. The DIET and DIET+CE groups will have a weekly nutritional consultation at the lab as well as a weekly check-in with the nutritionist via text, phone, or email. Participants will be randomly assigned a group after completing the screening session and prior to the experimental session.


Condition or disease Intervention/treatment Phase
Weight Loss Cold Exposure Appetitive Behavior Behavioral: Caloric Restriction Other: Cold intervention Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This study is an 8 week weight loss intervention with 3 randomly assigned groups: DIET, cold exposure (CE), and DIET+CE. Participants in the CE and DIET+CE groups will report to the laboratory every 2nd day for the 8 week intervention to undergo cold exposure. The DIET and DIET+CE groups will have a weekly nutritional consultation at the lab as well as a weekly check-in with the nutritionist via text, phone, or email.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cold Exposure, Appetite Control and Weight Loss in Individuals Living With Obesity
Actual Study Start Date : February 1, 2022
Estimated Primary Completion Date : August 31, 2022
Estimated Study Completion Date : October 31, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Only diet group
Dietary energy prescription at -30% of Energy requirements (50% carbohydrate; 30% fat; 20% protein) during 8 weeks. Follow up with a registered dietitian.
Behavioral: Caloric Restriction
-30% of participants total energy requirements

Experimental: Only cold exposure group
No dietary intervention. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 18 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during 90 min.
Other: Cold intervention
Sessions of 90min each every 2nd day involving cold exposure

Experimental: Combined diet + cold exposure group
Dietary energy prescription at -30% of Energy requirements (50% carbohydrate; 30% fat; 20% protein). Follow up with a registered dietitian. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 18 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during during 90 min.
Behavioral: Caloric Restriction
-30% of participants total energy requirements




Primary Outcome Measures :
  1. Change from baseline energy intake at 8 weeks [ Time Frame: 8 weeks ]
    Energy intake will be measured both in the laboratory and in the free-living state for 3 days with a validated food menu (McNeil, 2012) and the Food Processor SQL from ESHA Research, Inc. Measures will be taken at baseline and after intervention.

  2. Change from baseline in fasting hunger using Visual Analogue scales at 8 weeks [ Time Frame: 8 weeks ]
    Measures of fasting hunger using Visual Analogue scales will be performed in fasting state (12h) at baseline and in the end of the weight loss intervention

  3. Change from baseline in fasting desire to eat using Visual Analogue scales at 8 weeks [ Time Frame: 8 weeks ]
    Measures of fasting desire to eat using Visual Analogue scales will be performed in fasting state (12h) at baseline and in the end of the weight loss intervention

  4. Change from baseline fasting fullness using Visual Analogue scales at 8 weeks [ Time Frame: 8 weeks ]
    Measures of fasting fullness using Visual Analogue scales will be performed in fasting state (12h) at baseline and in the end of the weight loss intervention

  5. Change from baseline in fasting prospective food consumption using Visual Analogue scales at 8 weeks [ Time Frame: 8 weeks ]
    Measures of fasting prospective food consumption using Visual Analogue scales will be performed in fasting state (12h) at baseline and in the end of the weight loss intervention

  6. Change from baseline in post-prandial hunger using Visual Analogue scales at 8 weeks [ Time Frame: 8 weeks ]
    Measures of post-prandial hunger using Visual Analogue scales will be taken at 30,60,90,120,150,180min after breakfast at baseline and in the end of the weight loss intervention

  7. Change from baseline in post-prandial desire to eat using Visual Analogue scales at 8 weeks [ Time Frame: 8 weeks ]
    Measures of post-prandial desire to eat using Visual Analogue scales will be taken at 30,60,90,120,150,180min after breakfast at baseline and in the end of the weight loss intervention

  8. Change from baseline in post-prandial fullness using Visual Analogue scales at 8 weeks [ Time Frame: 8 weeks ]
    Measures of post-prandial fullness using Visual Analogue scales will be taken at 30,60,90,120,150,180min after breakfast at baseline and in the end of the weight loss intervention

  9. Change from baseline in post-prandial prospective food consumption using Visual Analogue scales at 8 weeks [ Time Frame: 8 weeks ]
    Measures of post-prandial prospective food consumption using Visual Analogue scales will be taken at 30,60,90,120,150,180min after breakfast at baseline and in the end of the weight loss intervention


Secondary Outcome Measures :
  1. Change from baseline in Resting energy expenditure at 8 weeks [ Time Frame: 8 weeks ]
    Resting energy expenditure will be measured at baseline and in the end the intervention

  2. Changes from baseline in post-prandial explicit liking using the LFPQ at 8 weeks [ Time Frame: 8 weeks ]
    explicit liking will be measured using a tool called Leeds Preference Food Questionnaire. Measures will be taken at baseline and at the end of the intervention

  3. Changes from baseline in post-prandial explicit wanting using the LFPQ at 8 weeks [ Time Frame: 8 weeks ]
    explicit wanting will be measured using a tool called Leeds Preference Food Questionnaire. Measures will be taken at baseline and at the end of the intervention

  4. Changes from baseline in post-prandial implicit wanting using the LFPQ at 8 weeks [ Time Frame: 8 weeks ]
    implicit wanting will be measured using a tool called Leeds Preference Food Questionnaire. Measures will be taken at baseline and at the end of the intervention

  5. Changes from baseline in olfaction using the 'Sniffin Sticks' tests at 8 weeks [ Time Frame: 8 weeks ]
    Olfaction will be measured using the Sniffin' Sticks (Burghart Instruments, Wedel, Germany), a 3-test battery of odorized markers that measure odor detection threshold, odor discrimination, and odor identification at 90 min after breakfast at baseline and after intervention

  6. Changes from baseline in shivering response activity at 8 weeks [ Time Frame: 8 weeks ]

    Changes in shivering response will be measured by surface electromyography (Delsys, Boston, MA, 02215, USA) from 7 muscles on the right side of the body:

    trapezius, latissimus dorsi, pectoralis major, vastus lateralis, rectus femoris, vastus medialis, and biceps femoris. EMG will be collected at 1000Hz and analyzed using a custom-designed MATLAB algorithms (Mathworks, Natick, MA) at baseline and after intervention.


  7. Changes from baseline in thermal comfort at 8 weeks [ Time Frame: 8 weeks ]
    Changes in thermal comfort will be measured using a LIKERT scale type (-5 to +5) at baseline and after the intervention

  8. Changes from baseline in thermal sensation at 8 weeks [ Time Frame: 8 weeks ]
    Changes in thermal sensation will be measured using a LIKERT scale type (-5 to +5) at baseline and after the intervention

  9. Changes from baseline in total Ghrelin (EZGRT-89K) at 8 weeks [ Time Frame: 8 weeks ]
    Blood samples will be collected fasting and at 30-min interval for 3 h in tubes containing EDTA and Aprotinin (anti-protease). Changes in total Ghrelin will be assayed with commercially available ELISA (Millipore, Billerica, MA 01821 USA) at baseline and after the intervention.

  10. Changes from baseline in total Leptin (EZHL-80SK) at 8 weeks [ Time Frame: 8 weeks ]
    Blood samples will be collected fasting and at 30-min interval for 3 h in tubes containing EDTA and Aprotinin (anti-protease). Changes in total Leptin will be assayed with commercially available ELISA (Millipore, Billerica, MA 01821 USA) at baseline and after the intervention.

  11. Changes from baseline in total GLP-1 (EZGLP1T-36K) at 8 weeks [ Time Frame: 8 weeks ]
    Blood samples will be collected fasting and at 30-min interval for 3 h in tubes containing EDTA and Aprotinin (anti-protease). Changes in total GLP-1 will be assayed with commercially available ELISA (Millipore, Billerica, MA 01821 USA) at baseline and after the intervention.

  12. Changes from baseline in total PYY (EZHPYYT66K) at 8 weeks [ Time Frame: 8 weeks ]
    Blood samples will be collected fasting and at 30-min interval for 3 h in tubes containing EDTA and Aprotinin (anti-protease). Changes in total PYY will be assayed with commercially available ELISA (Millipore, Billerica, MA 01821 USA) at baseline and after the intervention.

  13. Changes from baseline in body composition at 8 weeks [ Time Frame: 8 weeks ]
    Changes in body composition will be measured using a DXA (Lunar Prodigy, GE Medical Systems) at baseline and after intervention.

  14. Changes from baseline in body weight at 8 weeks [ Time Frame: 8 weeks ]
    Baseline and post intervention changes of body weight will be measured using a BWB-800AS Digital Scale from Tanita Corporation of America, Inc. Arlington Heights, Illinois, USA).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Present a 27≥BMI,
  • Present a waist circumference >88 cm
  • Must be weight-stable (±2 kg last 6 months)
  • Must be sedentary (<2 times/week of 30 min of continuous exercise)
  • Must be able to read in English
  • Must to present no history of alcohol or drugs abuse

In addition, Women will be included if:

• Must be pre-menopausal with a regular menstrual cycle

Exclusion Criteria:

  • present any history or evidence of cardiovascular disease
  • present any history or evidence of peripheral vascular disease
  • present any history or evidence of stroke
  • present a current diagnosis of an axis 1 psychiatric disorder (i.e. mood, anxiety and eating disorders);
  • be insulin dependent (75g oral glucose tolerance test)
  • present a known renal and/or liver disease
  • asthma requiring therapy
  • plasma cholesterol > 8 mmol/L
  • systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg
  • present previous history of inflammation disease
  • present previous history of cancer
  • present untreated thyroid or pituitary disease
  • present a regular consumption of medications that could affect cardiovascular function and/or metabolism (i.e. MAO inhibitors, pressor agents, warfarin, anticonvulsants, phenylbutazone, or tricyclic antidepressants)
  • present food allergies
  • be smoker
  • present alcohol intake that exceeds recommendations or alcoholism
  • present current addictions to opiates, cocaine or stimulants
  • be pregnant or planning to become pregnant over the course of the study
  • be peri- or post-menopausal
  • have had surgically induced menopause

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05076357


Contacts
Layout table for location contacts
Contact: Luzia Jaeger-Hintze, PhD 613-562-5800 ext 7361 lhintze@uottawa.ca
Contact: Eric Doucet, Prof 613-562-5800 ext 7364 edoucet@uottawa.ca

Locations
Layout table for location information
Canada, Ontario
University of Ottawa Recruiting
Ottawa, Ontario, Canada, K1N6N5
Contact: Luzia Jaeger Hintze, PhD       lhintz@uottawa.ca   
Sponsors and Collaborators
University of Ottawa
Canadian Institutes of Health Research (CIHR)
Investigators
Layout table for investigator information
Principal Investigator: Eric Doucet, PhD University of Ottawa
Layout table for additonal information
Responsible Party: Eric Doucet, Full Professor, University of Ottawa
ClinicalTrials.gov Identifier: NCT05076357    
Other Study ID Numbers: H-09-19-4928
First Posted: October 13, 2021    Key Record Dates
Last Update Posted: April 27, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eric Doucet, University of Ottawa:
weight loss
appetite
cold exposure
obesity
nutritional intervention
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity
Body Weight
Weight Loss
Overnutrition
Nutrition Disorders
Overweight
Body Weight Changes